10q10k10q10k.net
Invivyd, Inc.

Invivyd, Inc.IVVDEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing broadly neutralizing antibody therapies to prevent and treat serious viral infectious diseases. Its core research and development pipeline targets high-burden respiratory pathogens including respiratory syncytial virus, catering to unmet medical needs of global patient groups.

Top Holders

Holder% OwnedSharesChangeAs of
Adimab, LLC19.70%
21.7M
—2024-01-22
Maverick Capital, Ltd.9.90%
11.8M
▲ +1.40pp2024-11-14
Deep Track Capital, LP9.17%
11.0M
▲ +1.61pp2024-11-14
FMR LLC6.13%
7.3M
▼ -1.51pp2024-11-12
Polaris Venture Partners V, L.P.2.60%
3.1M
—2024-12-12
GV 2019 GP, L.L.C.0.00%
1.9K
—2024-11-08

Insider Transactions

Net 90d: −$354.2K · buys $0 / sells $354.2K
Range:
Action:
Role:
InsiderRoleAction
2026-02-18Allen Robert D. IIIChief Scientific OfficerSell (open market)
19.4K
$1.58$30.6K
2026-02-18Jill AndersenChief Legal Officer, SecretarySell (open market)
34.9K
$1.58$55.1K
2026-02-18Duke William E.Chief Financial OfficerSell (open market)
21.0K
$1.58$33.1K
2026-02-18Lee Timothy EdwardChief Commercial OfficerSell (open market)
21.0K
$1.58$33.1K
2026-02-18Julie GreenChief Human Resources OfficerSell (open market)
21.0K
$1.58$33.1K
2026-02-17Allen Robert D. IIIChief Scientific OfficerSell (open market)
18.2K
$1.54$28.0K
2026-02-17Jill AndersenChief Legal Officer, SecretarySell (open market)
32.8K
$1.54$50.5K
2026-02-17Duke William E.Chief Financial OfficerSell (open market)
19.7K
$1.54$30.3K
2026-02-17Lee Timothy EdwardChief Commercial OfficerSell (open market)
19.7K
$1.54$30.3K
2026-02-17Julie GreenChief Human Resources OfficerSell (open market)
19.7K
$1.54$30.3K
1–10 of 15
Page 1 / 2